Tumor Bacteria Burden Emerges as Key Predictor of Immunotherapy Resistance in Head and Neck Cancer
核心洞察
Cleveland Clinic researchers discovered that elevated bacterial levels within head and neck cancer tumors suppress immune response and drive resistance to immunotherapy, shifting focus beyond tumor genetics to the tumor microbiome.
Analysis of the CIAO clinical trial revealed that tumor bacterial burden was the only significant predictor of immunotherapy response, outperforming traditional biomarkers like PD-L1 (搜索) staining and tumor mutational burden.
Preclinical studies demonstrated that antibiotics (搜索) reduced tumor size and improved immune response by decreasing neutrophil infiltration and increasing T cell presence, while bacterial administration made tumors resistant to anti-PD-L1 (搜索) treatment.
Cleveland Clinic researchers have identified a critical factor in immunotherapy resistance that extends beyond traditional tumor genetics: the bacterial burden within cancerous tumors. Two complementary studies published simultaneously in Nature Cancer reveal that elevated levels of bacteria in the tumor microenvironment suppress immune response and drive resistance to immunotherapy in patients with head and neck squamous cell carcinoma (搜索) (HNSCC (搜索)).
The research team, led by Timothy Chan, M.D., Ph.D., chair of Cleveland Clinic's Department of Cancer Sciences, analyzed patient samples, preclinical models, and clinical trial data to validate their findings. "These studies shift the focus of immunotherapy resistance research beyond tumor genetics to unexpected factors like the tumor microbiome," said Dr. Chan. "By identifying bacteria as a key barrier to treatment, we're opening the door to new strategies for patient selection and targeted antibiotic therapies."
Tumor Bacterial Burden Outperforms Traditional Biomarkers
In the first study, researchers analyzed samples from the CIAO clinical trial, which evaluated neoadjuvant durvalumab (anti-PD-L1 (搜索)) with or without tremelimumab (anti-CTLA4 (搜索)) in 28 patients with resectable oropharyngeal HNSCC (搜索). Remarkably, tumor bacterial burden (TBB) - defined as the number of bacterial reads per million human reads - was the only significant predictor of immunotherapy response.
Traditional biomarkers failed to predict treatment outcomes. Neither PD-L1 (搜索) combined positivity score nor tumor mutational burden (TMB) showed significant association with immunotherapy response. Analysis of the tumor immune microenvironment revealed no immune cell populations significantly associated with response to immune checkpoint blockade (ICB).
Patients with high tumor bacterial burden had significantly lower response rates to immunotherapy. TBB was significantly lower in ICB responders compared to nonresponders and was significantly lower for participants who achieved major or partial pathological response.
Validation Across Multiple Cancer Types
The predictive value of TBB was validated in an independent Cleveland Clinic cohort of HNSCC (搜索) patients treated with ICB, where high TBB was associated with poor outcomes following immunotherapy. The researchers extended their analysis to the Hartwig non-small cell lung cancer (搜索) (NSCLC (搜索)) cohort, finding that TBB provided superior predictive performance with an area under the curve (AUC) of 0.74 compared to 0.58 for relative Fusobacterium abundance.
In multivariate regression analysis across multiple cancer types including NSCLC (搜索), HNSCC (搜索), urothelial carcinoma (搜索), mesothelioma (搜索), and colorectal cancer (搜索), TBB maintained predictive value while other bacterial markers lost significance. Importantly, this effect was specific to immunotherapy, as neither TBB nor specific bacterial species were associated with response to chemotherapy or targeted therapy.
Mechanistic Insights: Neutrophils Drive Immunosuppression
The research revealed that elevated bacterial levels attract neutrophils, white blood cells that fight infection but can suppress the immune system needed for immunotherapy effectiveness. Analysis of TCGA data from 157 HNSCC (搜索) patients showed that high TBB was strongly associated with increased neutrophil abundance and reduced adaptive antitumor immune cells, including T cells and B cells.
The intratumoral neutrophil-to-lymphocyte ratio (tNLR) was significantly positively correlated with TBB and was associated with worse response to ICB. This correlation was validated across multiple cancer types, suggesting a universal mechanism of bacterial-mediated immunosuppression.
Daniel McGrail, Ph.D., assistant staff in the Center for Immunotherapy & Precision Immuno-Oncology, explained: "By uncovering the tumor microbiome's role in immunotherapy resistance, these studies mark a significant step forward in understanding the complex interactions between cancer and the immune system."
Preclinical Validation and Therapeutic Implications
Preclinical studies using murine models of head and neck cancer provided mechanistic validation. Researchers found that intratumoral bacteria accumulated in orthotopic tongue tumors but were absent in subcutaneous tumors. Broad-spectrum antibiotics (搜索) administered through drinking water effectively depleted bacterial load in orthotopic tumors.
Antibiotic treatment significantly attenuated tumor growth in bacteria-rich orthotopic sites but had no effect at low-bacterial-burden subcutaneous sites. The treatment resulted in decreased neutrophils and increased CD8 (搜索) T cells, directly implicating intratumoral bacteria in remodeling the tumor immune microenvironment.
To test causality, researchers experimentally increased bacterial burden through oral administration of tumor-associated bacteria including Fusobacterium, Prevotella, and Campylobacter. All three bacteria increased intratumoral bacterial load, led to increased neutrophil infiltration, reduced CD3 (搜索)+ T cells, and were sufficient to abrogate response to anti-PD-L1 (搜索) treatment in previously sensitive tumors.
Clinical Translation and Future Directions
Building on these discoveries, Natalie Silver, M.D., M.S., director of Head and Neck Cancer Research, launched a clinical trial funded by the American Cancer Society and VeloSano (搜索) to test whether antibiotics (搜索) can lower tumor microbiome levels and boost immunotherapy response in HNSCC (搜索) patients.
"Immunotherapy is a promising treatment option for patients with head and neck cancer, but the majority unfortunately do not respond," Dr. Silver said. "Our research examines how bacteria influence treatment failure. This can help us identify patients most likely to benefit from immunotherapy, with the goal of avoiding unnecessary risk and exposure."
The second study analyzed data from the Javelin HN100 Phase III clinical trial, confirming that patients with high tumor bacterial levels had poorer outcomes with immunotherapy compared to standard chemoradiotherapy. Interestingly, analysis of clinical benefit from anti-PD(L)1 treatment in HNSCC (搜索) patients revealed that those treated with concurrent antibiotics (搜索) exhibited significantly improved responses to immunotherapy.
Implications for Precision Medicine
The findings suggest that TBB could serve as a biomarker for ICB response in HNSCC (搜索) patients, potentially used to stratify patients more likely to benefit from neoadjuvant ICB treatment. Alternatively, bacterial abundance could identify patients who may benefit from antibiotic use in combination with immunotherapy.
The research indicates that restricting antibiotic administration to patients with high-bacterial-load tumors may optimize therapeutic balance by preserving immunostimulatory benefits while minimizing adverse effects on the gut-immune axis. This approach could be refined through targeted antibiotics (搜索) or alternative bacteria-directed strategies that selectively eliminate intratumoral bacteria while preserving commensal gut microbiota.
The studies demonstrate that total bacterial abundance, rather than specific bacterial species, drives immunosuppression. Expression of neutrophil chemoattractants was induced by multiple bacteria in HNSCC (搜索) cell lines, independent of bacterial type, suggesting that immune modulation is primarily driven by overall intratumoral bacterial abundance rather than specific pathogenic bacteria.
These findings have broad implications for cancer treatment, potentially extending beyond HNSCC (搜索) to other tumor types with significant bacterial burden. Ongoing clinical trials are assessing the potential of antibiotics (搜索) to reduce intratumoral microbial load and will inform the design of future combination immunotherapy strategies.